Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis

NCT00663052 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00663052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00663052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2008
Completion date
January 31, 2010
Enrollment
273 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriasis